One-year outcomes of coronary artery bypass graft surgery versus percutaneous coronary intervention with multiple stenting for multisystem disease: A meta-analysis of individual patient data from randomized clinical trials

被引:107
作者
Mercado, N
Wijns, W
Serruys, PW
Sigwart, U
Flather, MD
Stables, RH
O'Neill, WW
Rodriguez, A
Lemos, PA
Hueb, WA
Gersh, BJ
Booth, J
Boersma, E
机构
[1] Erasmus Univ, Med Ctr, Thoraxctr, Dept Cardiol,Clin Epidemiol Unit, NL-3015 GD Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Thoraxctr, Dept Intervent Cardiol, NL-3015 GD Rotterdam, Netherlands
[3] Onze Lieve Vrouw Hosp, Ctr Cardiovasc, Aalst, Belgium
[4] Univ Hosp Geneva, Div Cardiol, Geneva, Switzerland
[5] Royal Brompton & Harefield NHS Trust, Clin Trials & Evaluat Unit, London, England
[6] Ctr Cardiothorac, Liverpool, Merseyside, England
[7] William Beaumont Hosp, Dept Med, Royal Oak, MI 48072 USA
[8] William Beaumont Hosp, Div Cardiol, Royal Oak, MI 48072 USA
[9] Otamendi Hosp, Buenos Aires, DF, Argentina
[10] Univ Sao Paulo, Inst Heart, Sao Paulo, Brazil
[11] Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, Rochester, MN 55905 USA
关键词
D O I
10.1016/j.jtcvs.2004.12.049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: We aimed to provide a quantitative analysis of the 1-year clinical outcomes of patients with multisystem coronary artery disease who were included in recent randomized trials of percutaneous coronary intervention with multiple stenting versus coronary artery bypass graft surgery. Methods: An individual patient database was composed of 4 trials (Arterial Revascularization Therapies Study, Stent or Surgery Trial, Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty Versus Coronary Artery Bypass Surgery in Multivessel Disease 2, and Medicine, Angioplasty, or Surgery Study 2) that compared percutaneous coronary intervention with multiple stenting (N = 1518) versus coronary artery bypass graft surgery (N = 1533). The primary clinical end point of this study was the combined incidence of death, myocardial infarction, and stroke at 1 year after randomization. Secondary combined end points included the incidence of repeat revascularization at 1 year. All analyses were based on the intention-to-treat principle. Results: After 1 year of follow-up, 8.7% of patients randomized to percutaneous coronary intervention with multiple stenting versus 9.1% of patients randomized to coronary artery bypass graft surgery reached the primary clinical end point (hazard ratio 0.95 and 95% confidence interval 0.74-1.2). Repeat revascularization procedures occurred more frequently in patients allocated to percutaneous coronary intervention with multiple stenting compared with coronary artery bypass graft surgery (18% vs 4.4%; hazard ratio 4.4 and 95% confidence interval 3.3-5.9). The percentage of patients who were free from angina was slightly lower after percutaneous coronary intervention with multiple stenting than after coronary artery bypass graft surgery (77% vs 82%; P = .002). Conclusions: One year after the initial procedure, percutaneous coronary intervention with multiple stenting and coronary artery bypass graft surgery provided a similar degree of protection against death, myocardial infarction, or stroke for patients with multisystem disease. Repeat revascularization procedures remain high after percutaneous coronary intervention, but the difference with coronary artery bypass graft surgery has narrowed in the era of stenting.
引用
收藏
页码:512 / 519
页数:8
相关论文
共 23 条
[1]   Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease - The bypass angioplasty revascularization investigation (BARI) [J].
Alderman, E ;
Bourassa, M ;
Brooks, MM ;
Califf, R ;
Chaitman, B ;
Detre, K ;
Faxon, DP ;
Feit, F ;
Frye, RL ;
Hardison, RM ;
Holmes, D ;
Holubkov, R ;
Kouchoukos, N ;
Krone, R ;
Rogers, W ;
Rosen, AD ;
Schaff, H ;
Schwartz, L ;
Siewers, AS ;
Sopko, G ;
SuttonTyrrell, K ;
Whitlow, P .
CIRCULATION, 1997, 96 (06) :1761-1769
[2]  
Alderman EL, 2000, J AM COLL CARDIOL, V35, P1122
[3]   Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features [J].
Brener, SJ ;
Lytle, BW ;
Casserly, IP ;
Schneider, JP ;
Topol, EJ ;
Lauer, MS .
CIRCULATION, 2004, 109 (19) :2290-2295
[4]   Individual patient-versus literature-based meta-analysis of survival data: Time to event and event rate at a particular time can make a difference, an example based on head and neck cancer [J].
Duchateau, L ;
Pignon, JP ;
Bijnens, L ;
Bertin, S ;
Bourhis, J ;
Sylvester, R .
CONTROLLED CLINICAL TRIALS, 2001, 22 (05) :538-547
[5]   Indications for intracoronary stent placement: the European view [J].
Eeckhout, E ;
Wijns, W ;
Meier, B ;
Goy, JJ .
EUROPEAN HEART JOURNAL, 1999, 20 (14) :1014-1019
[6]  
Gaziano J. M., 2001, Heart Disease, V7, P1
[7]   A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: One- to eight-year outcomes [J].
Hoffman, SN ;
TenBrook, JA ;
Wolf, MP ;
Pauker, SG ;
Salem, DN ;
Wong, JB .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (08) :1293-1304
[8]   The medicine, angioplasty, or surgery study (MASS-II):: A randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease one-year results [J].
Hueb, W ;
Soares, PR ;
Gersh, BJ ;
César, LAM ;
Luz, PL ;
Puig, LB ;
Martinez, EM ;
Oliveira, SA ;
Ramires, JAF .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (10) :1743-1751
[9]   Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world" -: The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry [J].
Lemos, PA ;
Serruys, PW ;
van Domburg, RT ;
Saia, F ;
Arampatzis, CA ;
Hoye, A ;
Degertekin, M ;
Tanabe, K ;
Daemen, J ;
Liu, TKK ;
McFadden, E ;
Sianos, G ;
Hofma, SH ;
Smits, PC ;
van der Giessen, WJ ;
de Feyter, PJ .
CIRCULATION, 2004, 109 (02) :190-195
[10]   Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus - Results of the EPISTENT (Evaluation of Platelet IIb/IIIa inhibitor for Stenting Trial) diabetic substudy [J].
Marso, SP ;
Lincoff, AM ;
Ellis, SG ;
Bhatt, DL ;
Tanguay, JF ;
Kleiman, NS ;
Hammoud, T ;
Booth, JE ;
Sapp, SK ;
Topol, EJ .
CIRCULATION, 1999, 100 (25) :2477-2484